New Precision Medicine Trial Opens for 20 High-Risk Neuroblastoma Patients

Neuroblastoma is an aggressive childhood cancer that occurs in children less than 6 years of age. The first challenge is that 20 percent of children are unable to attain remission. The primary goal of this study is to evaluate the feasibility of using molecular guided therapy in combination with standard chemotherapy to increase response. The second challenge in neuroblastoma is that approximately 40 percent of children relapse. The second goal is to follow upfront chemotherapy with maintenance therapy using DFMO to prevent relapse in patients with newly diagnosed high-risk neuroblastoma. If this pilot of 20 patients is successful, the NMTRC will further explore this as a new way of treating children with neuroblastoma with the hope of increasing overall survival.

Read more of the article here

Mind if we hang out
in your inbox?

We only email once or twice a month, always relevant to how we're working to beat neuroblastoma and other childhood cancers.

Thank you for subscribing!

Something went wrong.